Efavirenz induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir

被引：20

作者：

Duval, X

Le Moing, V

Longuet, P

Leport, C

Vildé, JL

Lamotte, C

Peytavin, G

Farinotti, R

机构：

[1] Hop Bichat Claude Bernard, Serv Malad Infect & Trop, F-75877 Paris, France

[2] Hop Bichat Claude Bernard, Serv Pharmacocinet Clin, F-75877 Paris, France

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 09期

基金：

英国惠康基金;

关键词：

D O I：

10.1128/AAC.44.9.2593-2593.2000

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

引用

收藏

页码：2593 / 2593

页数：1

相关论文

共 4 条

[1] Amprenavir
Adkins, JC
Faulds, D
[J]. DRUGS, 1998, 55 (06) : 837 - 842
[2] Ritonavir - Clinical pharmacokinetics and interactions with other anti-HIV agents
Hsu, A
Granneman, GR
Bertz, RJ
[J]. CLINICAL PHARMACOKINETICS, 1998, 35 (04) : 275 - 291
[3] WEAK BINDING OF VX-478 TO HUMAN PLASMA-PROTEINS AND IMPLICATIONS FOR ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS THERAPY
LIVINGSTON, DJ
PAZHANISAMY, S
PORTER, DJT
PARTALEDIS, JA
TUNG, RD
PAINTER, GR
[J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (05) : 1238 - 1245
[4] Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults
Sadler, BM
Hanson, CD
Chittick, GE
Symonds, WT
Roskell, NS
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) : 1686 - 1692